Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. (RETA) Stock Overview

Explore Reata Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

RETA●NASDAQ
HealthcareBiotechnology
$172.36
$0.04(0.02%)
U.S. Market is Open · 14:15

Reata Pharmaceuticals, Inc. (RETA)

Meyka AI Score

Z

Key Financials

Market Cap6.6B
P/E Ratio-20.07
EPS (TTM)$-2.60
ROE0.47%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$0.00

RETA Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Reata Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of RETA on the NASDAQ shows an RSI of N/A, suggesting the stock is in a an undetermined condition. Our forecasting models predict a 12-month price target of $0.00 for the NASDAQ listing.

Key metrics behind Reata Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -20.07 and a market capitalization of 6.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of RETA on the NASDAQ.

Price Performance (NASDAQ: RETA)

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
61.87%
6-Month Change
72.79%
Year-to-Date (YTD) Change
369.52%
1-Year Change
424.85%
3-Year Change
50.36%
5-Year Change
196.35%
All-Time (Max) Change
1218.75%

Contact Information

https://www.biogen.com/reata-pharma
972 865 2219
5320 Legacy Drive, Plano, TX, 75024

Company Facts

3,210 Employees
IPO DateMay 26, 2016
CountryUS

Frequently Asked Questions